These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22160041)

  • 1. Novel antibody-based therapies for acute lymphoblastic leukemia.
    Hoelzer D
    Hematology Am Soc Hematol Educ Program; 2011; 2011():243-9. PubMed ID: 22160041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoimmunotherapy in acute lymphoblastic leukemia.
    Hoelzer D; Gökbuget N
    Blood Rev; 2012 Jan; 26(1):25-32. PubMed ID: 21958552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
    Hoelzer D
    Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antibody-based therapy for acute lymphoblastic leukaemia.
    Gökbuget N; Hoelzer D
    Best Pract Res Clin Haematol; 2006; 19(4):701-13. PubMed ID: 16997178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
    Le Jeune C; Thomas X
    Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.
    Gökbuget N; Hoelzer D
    Ann Hematol; 2004 Apr; 83(4):201-5. PubMed ID: 14648023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of antibody therapy in ALL.
    Ai J; Advani A
    Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
    Jabbour E; Pui CH; Kantarjian H
    JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
    Farhadfar N; Litzow MR
    Leuk Res; 2016 Oct; 49():13-21. PubMed ID: 27521873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
    Wei G; Wang J; Huang H; Zhao Y
    J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody therapy for acute lymphoblastic leukemia.
    Portell CA; Advani AS
    Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
    Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
    Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
    Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging biological therapies to treat acute lymphoblastic leukemia.
    Huguet F; Tavitian S
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):107-121. PubMed ID: 27820973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
    Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
    Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies in acute lymphoblastic leukemia.
    Jabbour E; O'Brien S; Ravandi F; Kantarjian H
    Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry.
    Pevna M; Doubek M; Coupek P; Stehlikova O; Klabusay M
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):411-8. PubMed ID: 25066039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.